Contraindicate puberty blocking and gender-affirming hormones in prepubertal children
STEP 1 — Gather Information
Collect patient age, Tanner stage (prepubertal defined as G1/B1), confirmed diagnosis of GD/gender incongruence per DSM-5/ICD-10 criteria, psychosocial history, and ensure no pubertal changes are present; if any data are missing, defer decision until information is obtained.
STEP 2 — Rule In / Rule Out
Is the child prepubertal (Tanner G1/B1) with a confirmed diagnosis of GD/gender incongruence? If yes, proceed to contraindication pathway; if no, evaluate for puberty-appropriate hormone therapy or alternative management.
STEP 3 — Classify or Stratify
Classify hormone therapy as contraindicated in this prepubertal child with GD/gender incongruence based on strong recommendation against treatment.
STEP 4 — Decide
Withhold puberty blocking and gender-affirming hormones; initiate psychosocial support, monitor for pubertal onset every 3–6 months, and reassess hormone therapy eligibility after puberty begins.
Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on bone age or parental report to determine pubertal status; do not treat based on social transition alone; do not ignore comorbid psychiatric conditions that require separate management; do not use hormones to treat non‑GD conditions such as anxiety or depression; do not initiate blockers or sex steroids in prepubertal children even if they have socially transitioned.
Concrete Clinical Example
A 7‑year‑old assigned male at birth presents with persistent insistence of being female, preference for female toys and clothing, and distress when referred to as male. Parents inquire about starting puberty blockers to prevent future masculinization. Evaluation confirms Tanner stage G1/B1, DSM‑5 criteria for GD are met, and no pubertal changes are observed. Following the guideline, clinicians decline hormone treatment, provide gender‑affirming psychosocial support, and schedule reevaluation at the first signs of puberty.
Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658